- ►diabetesjournals.org DA Stoffers, BM Desai, DD DeLeon, RA … - Diabetes, 2003 - Am Diabetes Assoc Uteroplacental insufficiency resulting in fetal growth retardation is a common
complication of pregnancy and a significant cause of perinatal morbidity and
mortality. Epidemiological studies show an increased incidence of type 2 ... Cited by 88 - Related articles - BL Direct - All 4 versions
Q Wang, P Brubaker - Diabetologia, 2002 - Springer Aims/hypothesis. Glucagon-like peptide-1 ameliorates the symptoms of diabetes
through stimulation of insu- lin secretion and enhancement of beta-cell mass. We
have therefore investigated the effects of glucagon- like peptide-1 on the ... Cited by 137 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org C Tourrel, D Bailbe, M Lacorne, MJ Meile, M … - Diabetes, 2002 - Am Diabetes Assoc In the Goto-Kakizaki (GK) rat, a genetic model of type 2 diabetes, the neonatal
β-cell mass deficit is considered to be the primary defect leading to basal
hyperglycemia, which is detectable for the first time 3 weeks after birth. ... Cited by 151 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org C Tourrel, D Bailbé, MJ Meile, M Kergoat, B … - Diabetes, 2001 - Am Diabetes Assoc In neonatal Wistar rats injected with streptozotocin (STZ) at birth (n0-STZ
model), a recognized model of β-cell regeneration, we investigated the capacity
of early treatment with glucagon-like peptide 1 (GLP-1) or exendin-4 to ... Cited by 171 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org DD De León, S Deng, R Madani, RS Ahima, DJ … - Diabetes, 2003 - Am Diabetes Assoc A reduction in β-cell mass is an important causative factor in type 1 and type
2 diabetes. Glucagon-like peptide-1 (GLP-1) and the long-acting agonist exendin
4 (Ex-4) expand β-cell mass by stimulating neogenesis and proliferation. ... Cited by 105 - Related articles - BL Direct - All 6 versions
- ►glucagon.com [PDF] Y Li, T Hansotia, B Yusta, F Ris, PA Halban, … - Journal of Biological Chemistry, 2003 - ASBMB Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments β
cell mass via activation of β cell proliferation and islet neogenesis. We
examined whether GLP-1 receptor signaling modifies the cellular ... Cited by 252 - Related articles - BL Direct - All 7 versions
- ►jbc.org RA Simmons, I Suponitsky-Kroyter, MA Selak - Journal of Biological Chemistry, 2005 - ASBMB A key adaptation enabling the fetus to survive in a limited energy environment
may be the reprogramming of mitochondrial function, which can have deleterious
effects. Critical questions are whether mitochondrial dysfunction ... Cited by 47 - Related articles - BL Direct - All 7 versions
[CITATION] Intrauterine growth retardation leads to type II diabetes in adulthood in the rat
- ►physiology.org JM Egan, GS Meneilly, D Elahi - American Journal of Physiology- Endocrinology And …, 2003 - Am Physiological Soc A gut insulinotropic peptide, glucagon-like peptide-1 (GLP-1), when given
continuously subcutaneously, has been shown to be an effective agent to treat
type 2 diabetes. Because of inactivation by dipeptidyl peptidase IV (DPP ... Cited by 80 - Related articles - BL Direct - All 4 versions
- ►endojournals.org J Movassat, GM Beattie, AD Lopez, A Hayek - Journal of Clinical Endocrinology & Metabolism, 2002 - Endocrine Soc In addition to stimulating insulin secretion, glucagon-like peptide and its
long-acting analog exendin 4 have been reported to increase ß-cell mass by both
differentiation/neogenesis of precursor cells and enhanced replication of ... Cited by 68 - Related articles - BL Direct - All 6 versions
